Skip to main content
FEBS Open Bio logoLink to FEBS Open Bio
. 2017 Oct 21;7(12):1880–1890. doi: 10.1002/2211-5463.12322

Prediction of target genes for miR‐140‐5p in pulmonary arterial hypertension using bioinformatics methods

Fangwei Li 1, Wenhua Shi 1, Yixin Wan 2, Qingting Wang 1, Wei Feng 1, Xin Yan 1, Jian Wang 1, Limin Chai 1, Qianqian Zhang 1, Manxiang Li 1,
PMCID: PMC5715273  PMID: 29226075

Abstract

The expression of microRNA (miR)‐140‐5p is known to be reduced in both pulmonary arterial hypertension (PAH) patients and monocrotaline‐induced PAH models in rat. Identification of target genes for miR‐140‐5p with bioinformatics analysis may reveal new pathways and connections in PAH. This study aimed to explore downstream target genes and relevant signaling pathways regulated by miR‐140‐5p to provide theoretical evidences for further researches on role of miR‐140‐5p in PAH. Multiple downstream target genes and upstream transcription factors (TFs) of miR‐140‐5p were predicted in the analysis. Gene ontology (GO) enrichment analysis indicated that downstream target genes of miR‐140‐5p were enriched in many biological processes, such as biological regulation, signal transduction, response to chemical stimulus, stem cell proliferation, cell surface receptor signaling pathways. Kyoto Encyclopedia of Genes and Genome (KEGG) pathway analysis found that downstream target genes were mainly located in Notch, TGF‐beta, PI3K/Akt, and Hippo signaling pathway. According to TF–miRNA–mRNA network, the important downstream target genes of miR‐140‐5p were PPI, TGF‐betaR1, smad4, JAG1, ADAM10, FGF9, PDGFRA, VEGFA, LAMC1, TLR4, and CREB. After thoroughly reviewing published literature, we found that 23 target genes and seven signaling pathways were truly inhibited by miR‐140‐5p in various tissues or cells; most of these verified targets were in accordance with our present prediction. Other predicted targets still need further verification in vivo and in vitro.

Keywords: GO, KEGG, miR‐140‐5p, target gene, transcription factor


Abbreviations

GO

gene ontology

KEGG

kyoto encyclopedia of genes and genome

PAH

pulmonary arterial hypertension

PASMC

pulmonary arterial smooth muscle cell

TF

transcription factor

Pulmonary arterial hypertension (PAH) is a chronic progressive disease of pulmonary vasculature characterized by sustained elevation of pulmonary vascular resistance and pulmonary arterial pressure, consequently leading to right heart failure and eventual death 1. The pathogenesis of PAH is associated with genetic predisposition, inflammation, increase in vascular tone, elevation in pulmonary artery cell proliferation and resistance to apoptosis, and the presence of in situ thrombosis 2, 3, 4, 5. Effect of current treatment on PAH remains poor and available therapies to improve long‐term prognosis are limited 6, so exploring novel molecular mechanisms and generating therapeutic approaches are urgently needed.MicroRNAs (miRNAs) are small noncoding RNA molecules around 22 nucleotides long that bind the 3′‐untranslated region (UTR) of mRNA to degrade mRNA and therefore to negatively regulate relevant genes expression 7. miRNAs have the ability to target numerous genes mRNA, therefore potentially controlling a host of genes expression and the activity of multiple signaling pathways 8, 9, 10. Recent studies have shown that reduction in microRNA (miR)‐140‐5p is found in both patients with PAH and monocrotaline‐induced PAH models in rat, which is involved in the development of PAH 11, 12. Therefore, it is important to identify comprehensive downstream targets of miR‐140‐5p with bioinformatics analysis in PAH, and this might provide some critical information for the development and treatment of PAH. In this study, downstream target genes regulated by miR‐140‐5p and upstream transcription factors (TFs) regulating miR‐140‐5p expression were predicted, and the downstream target genes were analyzed for gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genome (KEGG) pathway. Next, the upstream TFs and downstream targets of miR‐140‐5p were determined according to the TF–miRNA–mRNA network. Finally, the direct downstream targets and relevant signaling pathways regulated by miR‐140‐5p were obtained in published literature and were compared with the predicted results of this study.

Materials and methods

Mature sequences of miR‐140‐5p in various species

Mature sequences of miR‐140‐5p in various species were obtained in the miRBase database (http://mirbase.org/index.shtml).

Target gene prediction of miR‐140‐5p

Identification of target genes is critical for characterizing the functions of miRNAs. In this study, miRanda (http://www.microrna.org/), TargetScan (http://www.targetscan.org/), RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid/submission.html), and miRDB (http://www.mirdb.org/) databases were used to predict the target genes of miR‐140‐5p. To make our predicted target genes more convincible, only the target genes predicted by at least three databases were selected for further analyses.

Database‐based GO and KEGG pathway enrichment analysis

Target mRNA of miR‐140‐5p supported by at least three databases were used for GO analysis to predict gene functions. Integration Discovery (DAVID) software, version 6.7 (http://david.abcC.ncifcrf.gov), was used to perform GO analysis to identify biological processes, cellular components, and molecular functions of these target genes. At the same time, the probable signaling pathways in which these target genes were enriched were analyzed by KEGG database (http://www.genome.jp/kegg/). The P‐value <0.05 was considered significant.

Upstream TFs prediction of miR‐140‐5p

Human miR‐140‐5p precursor was obtained in the miRBase database and its 5000 bp upstream was defined as the miR‐140‐5p promoter. The TFs of miR‐140‐5p were predicted using MOODS‐python software (version 1.9.3) in JASPAR database (http://jaspar.binf.ku.dk/), which includes various vertebrate TFs. The P‐value <0.0001 was considered significant.

Construction of the network for TF–miR‐140‐5p–mRNA

By merging the regulatory relationships between TFs and miR‐140‐5p, miR‐140‐5p and target genes, genes and genes (TF→miRNA, miRNA→gene and gene→gene), we constructed a comprehensive TF–miR‐140‐5p–mRNA regulatory network using Gephi software (release 0.8.1‐β, http://gephi.github.io/).

Screening target genes and signaling pathways inhibited by miR‐140‐5p in published studies

To obtain downstream target genes and signaling pathways modulated by miR‐140‐5p in published studies, a comprehensive electronic search of Web of Science and PubMed databases was performed until April 20, 2017. The keyword ‘miR‐140‐5p’ in the titles or abstracts was used, and then, studies exploring the targets of miR‐140‐5p were collected.

Results

Mature sequences of miR‐140‐5p in various species

Mature sequences of miR‐140‐5p in various species were obtained in the miRBase database. The pre‐miR‐140‐5p was located at position 69933081 ~ 69933180 of chromosome 16, and the gene ID of human miR‐140‐5p was MIMAT0000431. As shown in Table 1, mature sequences of miR‐140‐5p were highly conserved in various species and human miR‐140‐5p was chosen for further analyses.

Table 1.

Mature sequences of miR‐140‐5p in various species

ID Mature name Sequence
MIMAT0000151 mmu‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0000431 hsa‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0000573 rno‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0001159 gga‐miR‐140‐5p AGUGGUUUUACCCUAUGGUAG
MIMAT0001836 dre‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0002143 ssc‐miR‐140‐5p AGUGGUUUUACCCUAUGGUAG
MIMAT0006812 oan‐miR‐140‐5p CAGUGGUUUUACCCUAUGGU
MIMAT0006197 mml‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0012745 mdo‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0012926 eca‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0014557 tgu‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0015763 ppy‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0021765 aca‐miR‐140‐5p CAGUGGUUUUACCCUAUGGU
MIMAT0022552 ola‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0023767 cgr‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0025434 pol‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0026220 ccr‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0032359 ssa‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0035960 chi‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG
MIMAT0036560 tch‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUA
MIMAT0036719 oha‐miR‐140‐5p CAGUGGUUUUACCCUAUGGUAG

Prediction of target genes for miR‐140‐5p

As shown in Fig. 1, the number of predicted target genes of miR‐140‐5p in miRanda, TargetScan, RNAhybrid, and miRDB databases was 2370, 428, 1017, and 262, respectively. There were 482 target genes supported by at least two databases, 123 target genes predicted by at least three databases and five target genes supported by all four databases. The target genes of miR‐140‐5p predicted by at least three databases are listed in Table 2 and were used for further analyses.

Figure 1.

Figure 1

The number of predicted target genes of miR‐140‐5p.

Table 2.

The target genes of miR‐140‐5p predicted by at least three databases

ABCA1 ACSL6 ADAM10 ADAMTS5 ADCY6 ANKFY1
ANKIB1 AP2B1 BACH1 BAZ2B BCL9 BMP2
C1R CADM3 CAND1 CAPN1 CCNYL1 CELF1
CORO2A CREB CTCF CYTH2 DNM3 DOK4
DPP10 DPYSL2 EGR2 EIF4G2 ELAVL2 ENTPD5
EPB41L2 ERC2 FAM175B FBN1 FCHO2 FES
FGF9 FLRT2 FOXP2 FYCO1 GNG5 GIT1
HAND2 HDAC4 HDAC7 HDGFRP3 HNRNPH3 HS2ST1
HSPA13 IGSF3 IPO7 JAG1 KAT2B KBTBD2
KIF1B KLF6 KLF9 KLK10 LAMC1 LHFPL2
LMNB1 LPHN2 LRAT LRP4 LSM14B LYSMD3
MARK1 MED13 MMD MYCBP2 MYO10 NAA20
NAALADL2 NCKAP1 NCOA1 NCSTN NFE2L2 NLK
NPL NUCKS1 OSBPL6 PPPICC PAFAH1B2 PDGFRA
PPTC7 PDE7A PPP1R12A PALM2‐AKAP2 RBM39 RFX7
RNF19A RALA RAB10 SEPT2 STRADB SYS1
SLAIN1 SAMD4 SMOC2 SNX2 SRCAP SHROOM3
SIAH1 SLC30A5 SLC38A2 TTYH3 ST5 TLR4 TTK
TJP1 TSSK2 TSPAN12 TSC22D2 TTYH2 TGFBR1
UBR5 UBR5 VEZF1 VEGFA WNT1 WDFY3
YOD1 ZBTB10 ZNF800

GO enrichment analysis for predicted target genes of miR‐140‐5p

GO enrichment analysis was conducted for the target genes of miR‐140‐5p predicted by at least three databases. As shown in Table 3, the target genes of miR‐140‐5p were mainly located in basement membrane (< 0.05) and participated in the molecular functions of protein binding, activating transcription factor binding, ion binding, lipid binding, and so on (< 0.05). In addition, the target genes of miR‐140‐5p were involved in various biological processes, including biological regulation, metabolic process, cell communication, signal transduction, response to chemical stimulus, stem cell proliferation, cell surface receptor signaling pathway (< 0.05). Fig. 2 presents the number of target genes corresponding to each GO term.

Table 3.

Gene ontology (GO) analysis for predicted target genes of miR‐140‐5p

ID Term P‐value Genes annotated to the term
Biological processes
GO:0050794 Regulation of cellular process 5.39E‐06 VEGFA| FGF9| PPP1CC|Pin1|HDAC7|PDGFRA|TGFBR1|ADAM10…
GO:0050789 Regulation of biological process 9.05E‐06 FGF9|BMP2|LAMC1|NUMBL|PDGFRA|PPP1CC||ADAM10|TLR4|TGFBR1…
GO:0007154 Cell communication 5.69E‐05 WNT1|PPP1CC|PDGFRA|TLR4|HDAC7|ADAM10| BMP2|TGFBR1…
GO:0023052 Signaling 6.14E‐05 PDGFRA|PPP1CC|FGF9|WNT1|TGFBR1|BMP2|ADAM10|JAG1|TLR4…
GO:0044763 Single‐organism cellular process 8.73E‐05 VEGFA|FGF9|LAMC1|BMP2|TLR4|WNT1|TGFBR1|PDGFRA|PPP1CC…
GO:0065007 Biological regulation 9.89E‐05 VEGFA|BMP2|TLR4|CREB|PPP1CC|PDGFRA|ADAM10|TGFBR1…
GO:0007165 Signal transduction 0.00011 PPP1CC|PDGFRA|WNT1|TGFBR1|FGF9|VEGFA|NCSTN|TLR4|ADAM10…
GO:0042221 Response to chemical stimulus 0.00048 NUMBL|PPP1CC|PDGFRA|VEGFA|LAMC1|TGFBR1|FGF9|BMP2|ADAM10|TLR4…
GO:0072089 Stem cell proliferation 0.00087 ACSL6|NUMBL|RAB10|HAND2|WNT1|BMP2…
GO:0007166 Cell surface receptor signaling pathway 0.00370 TLR4|WNT1|BMP2|ADAM10|NCSTN|JAG1|PPP1CC|PDGFRA|FGF9…
GO:0050896 Response to stimulus 0.01555 PPP1CC|PDGFRA|WNT1|CREB|TGFBR1|VEGFA||FGF9|BMP2|ADAM10|TLR4…
GO:0019538 Protein metabolic process 0.02054 CREB|PPP1CC|PDGFRA|NUMBL|TLR4|ADAM10|BMP2|KAT2B|NCSTN| TGFBR1…
GO:0006464 Cellular protein modification process 0.03073 HDAC4|CREB|ADAM10|TLR4|TGFBR1|PPP1CC|PDGFRA…
Molecular functions
GO:0005515 Protein binding 2.53E‐07 TLR4|ADAM10|PDGFRA|WNT1|HDAC7|VEGFA|CREB|PPP1CC|TGFBR1|FGF9…
GO:0005488 Binding 0.00048 HDAC7|JAG|LMNB1|PDGFRA|ADAM10| TLR4|FGF9|KAT2B|TGFBR1…
GO:0033613 Activating transcription factor binding 0.00320 EGR2|NFE2L2|HDAC4|HDAC7|HAND2…
GO:0043167 Ion binding 0.00724 VEGFA|PPP1CC|ADAM10|PDGFRA|TGFBR1|HDAC4|FGF9|HDAC7…
GO:0008289 Lipid binding 0.04471 LAMC1|OSBPL6|FES|DNM3|MYO10|TLR4…
Cellular components
GO:0005604 Basement membrane 0.04119 FGF9|PDGFRA|TLR4|VEGFA|SMOC2…

Figure 2.

Figure 2

Gene ontology (GO) enrichment analysis for predicted target genes of miR‐140‐5p.

KEGG pathway analysis for predicted target genes of miR‐140‐5p

Enriched signaling pathways for the target genes of miR‐140‐5p identified by KEGG pathway analysis were ranked according to the P‐values. As shown in Table 4, the top rankings were related to Notch, cancer‐associated pathway, TGF‐beta, PI3K/Akt, HTLV infection, Hippo, HIF‐1, alcoholism signaling pathways, and so on (< 0.05); among them, Notch, TGF‐beta, PI3K/Akt, and Hippo signaling pathways were well known to be associated with the pathogenesis of PAH. Fig. 3 presents the rich factor, Q value, and gene number corresponding to each pathway term.

Table 4.

Kyoto Encyclopedia of Genes and Genome (KEGG) pathway analysis for predicted target genes of miR‐140‐5p

Term ID Sample number Background number P‐value Genes
Notch signaling pathway hsa04330 4 52 0.006408 JAG1|ADAM10|KAT2B|NCSTN
Pathways in cancer hsa05200 9 337 0.016384 FGF9|TGFBR1|VEGFA|SLC2A1|WNT1|BMP2|PDGFRA|LAMC1
Endocrine and other factor‐regulated calcium reabsorption hsa04961 3 48 0.022347 AP2B1|ADCY6|DNM3
HTLV‐I infection hsa05166 7 268 0.031935 TGFBR1|KAT2B|SLC2A1|EGR2|WNT1|PDGFRA|ADCY6
Regulation of actin cytoskeleton hsa04810 6 221 0.031935 PPP1R12A|NCKAP1|FGF9|GIT1|PDGFRA|PPP1CC
Pancreatic cancer hsa05212 3 66 0.031935 RALA|TGFBR1|VEGFA
Epithelial cell signaling in Helicobacter pylori infection hsa05120 3 66 0.031935 TJP1|GIT1|ADAM10
Proteoglycans in cancer hsa05205 6 231 0.033735 PPP1R12A|FGF9|VEGFA|WNT1|TLR4|PPP1CC
Adherence junction hsa04520 3 74 0.037848 NLK|TJP1|TGFBR1
Alcoholism hsa05034 5 183 0.038681 HDAC7|HDAC4|CREB3L1|GNG5|PPP1CC
PI3K‐Akt signaling pathway hsa04151 7 358 0.045545 FGF9|VEGFA|PDGFRA|LAMC1|TLR4|CREB|GNG5
Focal adhesion hsa04510 5 214 0.045545 PPP1R12A|VEGFA|PDGFRA|LAMC1|PPP1CC
Endocytosis hsa04144 5 212 0.045545 AP2B1|TGFBR1|GIT1|PDGFRA|DNM3
Viral carcinogenesis hsa05203 5 213 0.045545 HDAC7|HDAC4|KAT2B|EGR2|CREB3L1
Hepatitis B hsa05161 4 151 0.045545 TGFBR1|EGR2|TLR4|CREB3L1
Insulin secretion hsa04911 3 92 0.045545 SLC2A1|CREB3L1|ADCY6
GABAergic synapse hsa04727 3 89 0.045545 SLC38A2|GNG5|ADCY6
TGF‐beta signaling pathway hsa04350 3 83 0.045545 TGFBR1|SMAD4|BMP2
Gap junction hsa04540 3 96 0.045545 TJP1|PDGFRA|ADCY6
Hippo signaling pathway hsa04390 4 156 0.045565 TGFBR1|WNT1|BMP2|PPP1CC

Figure 3.

Figure 3

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis for predicted target genes of miR‐140‐5p.

Prediction of upstream TFs for miR‐140‐5p and construction of TF–miR‐140‐5p–mRNA network

The number of predicted TFs for miR‐140‐5p with P‐value <0.0001 was 393. To reduce false‐positive results, TFs with a quality score (Q‐score) less than 10 were filtered. As shown in Table 5, the remaining TFs, including PAX5, FOXI1, IRF1, FOSL1, RUNX2, were chosen for further analyses. Finally, by merging the regulatory relationships between TFs and miR‐140‐5p, miR‐140‐5p and target genes, as well as genes and genes, we built a comprehensive TF–miR‐140‐5p–mRNA regulatory network, as shown in Fig. 4.

Table 5.

Prediction of transcription factors and binding sites of miR‐140‐5p

Model ID Model name Hit position Strand Score Predicted site sequence
MA0014.2 PAX5 95 10.5663 gtctcactctgttgcccat
MA0014.2 PAX5 3874 11.6915 gtcttgctctgttgcccag
MA0025.1 NFIL3 722 10.0393 TTCTTACATAA
MA0035.3 Gata1 3391 10.0718 acagataaaaa
MA0036.2 GATA2 3391 10.4087 acagataaaaattt
MA0041.1 Foxd3 4529 + 10.4011 ttttgtttgttt
MA0042.1 FOXI1 984 + 11.5926 GGATGTTTGTTT
MA0042.1 FOXI1 4529 + 10.3990 ttttgtttgttt
MA0046.1 HNF1A 4949 + 10.3282 agttaataatttta
MA0050.2 IRF1 3825 + 11.0065 tttttctttttcttttctttc
MA0050.2 IRF1 3840 + 12.4803 tctttctttcttttttttttt
MA0050.2 IRF1 3844 + 10.0776 tctttcttttttttttttttt
MA0062.2 GABPA 1506 + 10.0387 ccggaagtcga
MA0073.1 RREB1 1164 10.9028 TTTTGGTTGTTGTTTTGTTT
MA0073.1 RREB1 3734 + 10.2056 caacaaaacaaaacaaaaca
MA0471.1 E2F6 143 10.6410 tcttcccgcct
MA0477.1 FOSL1 4238 11.2229 cctgagtcacc
MA0478.1 FOSL2 4239 10.3145 ctgagtcacct
MA0481.1 FOXP1 3756 + 10.2195 acaaaaaaaacacaa
MA0481.1 FOXP1 4018 10.3465 ttttgtttttttagt
MA0490.1 JUNB 4239 10.6046 ctgagtcacct
MA0491.1 JUND 2362 + 10.0256 GAAAATGATATCACA
MA0493.1 Klf1 4812 + 10.548 caccacaccca
MA0511.1 RUNX2 3813 + 11.453 tgtgtatgtggtttt
MA0515.1 Sox6 3772 10.2529 gaaacaatgg
MA0595.1 SREBF1 2000 10.1772 gtggcgtgat

Figure 4.

Figure 4

Regulatory network of TF–miR‐140‐5p–mRNA.

Screening target genes and signaling pathways modulated by miR‐140‐5p in published studies

A comprehensive electronic search of Web of Science and PubMed databases was performed until April 20, 2017, to obtain target genes and signaling pathways modulated by miR‐140‐5p in published studies. Finally, a total of 26 papers including 23 target genes and seven signaling pathways inhibited by miR‐140‐5p were obtained; most of them focus on the functions of miR‐140‐5p suppressing tumor growth, migration, and invasion in various tumor tissues and cells. Two recent studies have found that SMURF1 and Dumt1 are direct target genes of miR‐140‐5p in pulmonary arterial smooth muscle cells (PASMCs) and are involved in the pathogenesis of PAH. The details are shown in Table 6.

Table 6.

Target genes and signaling pathways modulated by miR‐140‐5p in published studies. NA, not available; HCC, hepatocellular carcinoma; T‐ALL, T‐cell acute lymphoblastic leukemia; Th1, T helper type 1; HSCC, hypopharyngeal squamous cell carcinoma; EPCs, endothelial progenitor cells; PH, pulmonary hypertension; HUVECs, human umbilical vein endothelial cells; BTC, biliary tract cancer; TSPCs, tendon stem/progenitor cells; LLC, Lewis lung cancer cells; MSCs, mesenchymal stem cells; TSCC, tongue squamous cell carcinoma

Author (Year) Target genes Inhibited pathways Associated functions Cell or tissue types
Hu (2017) VEGFA NA Inhibit cell proliferation and invasion, promote apoptosis Glioma tissues and cells
Meng (2017) HMGN5 NA Decrease cell resistance to chemotherapy Osteosarcoma tissues and cells
Yan (2017) Pin1 Pin1‐dependent cancer pathway Suppress tumor growth HCC tissues and cells
Correia (2016) TAL1 NA Suppress tumor growth T‐ALL cells
Guan (2016) STAT1 NA Suppress Th1 cell differentiation Th1 cells
Jing (2016) ADAM10 Notch1 signaling pathway Suppress tumor migration and invasion HSCC tissues and cells
Liu (2016) HDAC7 NA Protect EPCs EPCs
Lv (2016) Slug NA Inhibit cell migration and invasion HCC tissues
Rothman (2016) SMURF1 BMP signaling pathway Inhibit cell proliferation, migration, and PH development PASMCs, rat PH models
Su (2016) IGF2BP1 NA Decrease cell proliferation, migration, and invasion Cervical cancer cells and tissues
SUN (2016) VEGFA NA Decrease cell proliferation, migration, and tube formation HUVECs
Wei (2016) IP3k2 IP3 signaling pathway Promote chemotherapy‐induced autophagy Human osteosarcoma cells
Yu (2016) Septin 2 NA Suppress cell proliferation and colony formation BTC tissues and cells
Zhang (2016) Dnmt1 NA Inhibit cell proliferation, promote cell apoptosis Human PH tissues, human PASMCs
Barter (2015) FZD6 Wnt signaling pathway Promote chondrogenic differentiation Mesenchymal stem cells
Chen (2015) Pin1 NA Promote cell senescence TSPCs
Lan (2015) PDGFRA NA Inhibit cancer growth Human ovarian cancer tissues and cells
Zhai (2015) Smad2 TGF‐β signaling pathway Decrease cell invasion and proliferation Colorectal cancer stem cells
Zhang (2015) VEGFA NA Inhibit tumor progression Colorectal cancer tissues and cells
Zhang (2015) TGFBR1 TGF‐β signaling pathway Regulate adipocyte differentiation Bone marrow stromal cells
Li (2014) MMD ERK signaling pathway Inhibit cell proliferation LLCs
Hwang (2014) BMP2 BMP signaling pathway Suppress osteogenesis Human MSCs
Karlsen (2014) RALA NA Stimulate chondrogenesis MSCs
Yang (2014) ADAM10, LAMC1, HDAC7 NA Suppress migration and invasion TSCC tissues and cells
Shi (2013) FoxP2 NA Impair dendritic development and vocal learning Zebra finch brain tissues
Yang (2013) TGFBR1, FGF9 TGF‐β and ERK signaling pathway Suppress cell proliferation and tumor metastasis HCC tissues and cells

Discussion

Pulmonary arterial hypertension is a chronic life‐threatening condition requiring long‐term management 13, and its available therapies are limited 6. There is a clear and urgent need for new therapeutic options based on deeply exploring the pathogenesis of PAH. Previous studies have indicated that miR‐140‐5p is dramatically downregulated, which in turn causes the development of a variety of cancers by the loss of suppressing tumor cell migration and growth 14, 15, 16, 17. miR‐140‐5p has been recently found to be reduced in both PAH patients and MCT‐induced PAH models in rat 11, 12. However, the downstream targets regulated by miR‐140‐5p contributing to the development of PAH remain largely unknown.

In this study, we found that the target genes of miR‐140‐5p were enriched in many biological processes, such as biological regulation, metabolic process, cell communication, signal transduction, response to chemical stimulus, stem cell proliferation, cell surface receptor signaling pathway. In KEGG pathway analysis, the target genes of miR‐140‐5p were mainly located in Notch, TGF‐beta, PI3K/Akt, and Hippo signaling pathways. According to the TF–miRNA–mRNA network, the important genes potentially regulated by miR‐140‐5p included PPI, TGF‐betaR1, smad4, JAG1, ADAM10, FGF9, PDGFRA, VEGFA, TLR4, LAMC1, CREB, and the upstream TFs, which might regulate miR‐140‐5p expression including TAX5, FOXI, IRF1, GATA6, RUNX2. After thoroughly reviewing published literature, we found that 23 target genes and seven signaling pathways were truly inhibited by miR‐140‐5p in various tissues or cells; most of these downstream targets were in accordance with our present prediction.

Several studies have shown that activation of Notch3 pathway is involved in the pathogenesis of PAH 18, 19. We have previously shown that activation of Notch3 promotes PASMC proliferation and inhibition of Notch3 pathway prevents monocrotaline‐induced development of PAH in rat 20, 21. JAG1 and ADAM10 are indispensable components of Notch signaling pathway, which were predicted as downstream targets of miR‐140‐5p in our analysis, suggesting that lack of miR‐140‐5p might promote the development of PAH by upregulation of JAG1 and ADAM10 genes and therefore activation of Notch3 cascade. In addition, activation of TGF‐beta1/Smad4 signaling promotes a proliferative PASMC phenotype and induces PAH in rat 22, 23. We found that TGF‐betaR1 and smad4 were possible downstream targets of miR‐140‐5p, reduction in miR‐140‐5p in PAH might stimulate TGF‐beta1/Smad4 pathway by upregulating TGF‐betaR1 and smad4. Previous studies have demonstrated that PDGF, TLR4, VEGFA, and FGF contribute to the pathogenesis of PAH via activating various signaling pathways, especially PI3K/Akt cascade 24, 25, 26, 27, 28. CREB, an important transcription factor lying downstream of PI3K/Akt pathway, mediates the partial functions of PI3K/Akt 29. In our analysis, PDGF, TLR4, VEGFA, FGF, and CREB were positively predicted as downstream targets of miR‐140‐5p, implying that miR‐140‐5p negatively regulates the functions of PI3K/Akt cascade by targeting FGF9, PDGFRA, VEGFA, TLR4, or CREB gene. Recent studies have also shown that Hippo signaling is associated with the development of PAH, which can be activated by PPI 30, 31. Our present results suggested that PPI was a direct target gene of miR‐140‐5p and might mediate miR‐140‐5p regulation of Hippo signaling.

Our predicted network provided potential target genes and relevant signaling pathways that might be modulated by miR‐140‐5p contribution to the development of PAH. Several targets and pathways predicted in our analysis, such as TGF‐betaR1, ADAM10, FGF9, PDGFRA, VEGFA and Notch, PI3K/Akt, TGF‐beta cascades, have been demonstrated to mediate the effects of miR‐140‐5p on antiproliferation and prodifferentiation in several cell types in published studies 16, 17, 32, 33. While the other targets predicted in our study, including PPI, smad4, JAG1, LAMC1, TLR4, and CREB as well as Hippo signaling pathway, have not been confirmed in the published literature, they still need further verification in vivo and in vitro.

Author contributions

ML and FL designed the study; WS, YW, LC, and QW analyzed and interpreted the data; WF, XY, QZ, and JW organized the results; FL wrote the manuscript.

Acknowledgement

This work was supported by Chinese National Science Foundation (No. 81670051 and No. 81330002).

References

  • 1. Grant JS, White K, MacLean MR and Baker AH (2013) MicroRNAs in pulmonary arterial remodeling. Cell Mol Life Sci 70, 4479–4494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Higasa K, Ogawa A, Terao C, Shimizu M, Kosugi S, Yamada R, Date H, Matsubara H and Matsuda F (2017) A burden of rare variants in BMPR2 and KCNK3 contributes to a risk of familial pulmonary arterial hypertension. BMC Pulm Med 17, 57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Malenfant S, Neyron AS, Paulin R, Potus F, Meloche J, Provencher S and Bonnet S (2013) Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ 3, 278–293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Rabinovitch M (2012) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 122, 4306–4313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Vaillancourt M, Ruffenach G, Meloche J and Bonnet S (2015) Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can J Cardiol 31, 407–415. [DOI] [PubMed] [Google Scholar]
  • 6. McLaughlin VV (2011) Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 20, 262–269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Negi V and Chan SY (2017) Discerning functional hierarchies of microRNAs in pulmonary hypertension. JCI Insight 2, e91327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Bienertova‐Vasku J, Novak J and Vasku A (2015) MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment. J Am Soc Hypertens 9, 221–234. [DOI] [PubMed] [Google Scholar]
  • 9. Bockmeyer CL, Maegel L, Janciauskiene S, Rische J, Lehmann U, Maus UA, Nickel N, Haverich A, Hoeper MM, Golpon HA et al (2012) Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant 31, 764–772. [DOI] [PubMed] [Google Scholar]
  • 10. Caruso P, MacLean MR, Khanin R, McClure J, Soon E, Southgate M, MacDonald RA, Greig JA, Robertson KE, Masson R et al (2010) Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 30, 716–723. [DOI] [PubMed] [Google Scholar]
  • 11. Rothman AM, Arnold ND, Pickworth JA, Iremonger J, Ciuclan L, Allen RM, Guth‐Gundel S, Southwood M, Morrell NW, Thomas M et al (2016) MicroRNA‐140‐5p and SMURF1 regulate pulmonary arterial hypertension. J Clin Invest 126, 2495–2508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Zhang Y and Xu J (2016) MiR‐140‐5p regulates hypoxia‐mediated human pulmonary artery smooth muscle cell proliferation, apoptosis and differentiation by targeting Dnmt1 and promoting SOD2 expression. Biochem Biophys Res Commun 473, 342–348. [DOI] [PubMed] [Google Scholar]
  • 13. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F et al (2014) Definitions and diagnosis of pulmonary hypertension. Turk Kardiyol Dern Ars 42(Suppl 1), 55–66. [PubMed] [Google Scholar]
  • 14. Kai Y, Peng W, Ling W, Jiebing H and Zhuan B (2014) Reciprocal effects between microRNA‐140‐5p and ADAM10 suppress migration and invasion of human tongue cancer cells. Biochem Biophys Res Commun 448, 308–314. [DOI] [PubMed] [Google Scholar]
  • 15. Li W and He F (2014) Monocyte to macrophage differentiation‐associated (MMD) targeted by miR‐140‐5p regulates tumor growth in non‐small cell lung cancer. Biochem Biophys Res Commun 450, 844–850. [DOI] [PubMed] [Google Scholar]
  • 16. Yang H, Fang F, Chang R and Yang L (2013) MicroRNA‐140‐5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology 58, 205–217. [DOI] [PubMed] [Google Scholar]
  • 17. Jing P, Sa N, Liu X, Liu X and Xu W (2016) MicroR‐140‐5p suppresses tumor cell migration and invasion by targeting ADAM10‐mediated Notch1 signaling pathway in hypopharyngeal squamous cell carcinoma. Exp Mol Pathol 100, 132–138. [DOI] [PubMed] [Google Scholar]
  • 18. Yu YR, Mao L, Piantadosi CA and Gunn MD (2013) CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension. Am J Respir Cell Mol Biol 48, 647–654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Xia Y, Bhattacharyya A, Roszell EE, Sandig M and Mequanint K (2012) The role of endothelial cell‐bound Jagged1 in Notch3‐induced human coronary artery smooth muscle cell differentiation. Biomaterials 33, 2462–2472. [DOI] [PubMed] [Google Scholar]
  • 20. Zhang Y, Xie X, Zhu Y, Liu L, Feng W, Pan Y, Zhai C, Ke R, Li S, Song Y et al (2015) Inhibition of Notch3 prevents monocrotaline‐induced pulmonary arterial hypertension. Exp Lung Res 41, 435–443. [DOI] [PubMed] [Google Scholar]
  • 21. Song Y, Zhang Y, Jiang H, Zhu Y, Liu L, Feng W, Yang L, Wang Y and Li M (2015) Activation of Notch3 promotes pulmonary arterial smooth muscle cells proliferation via Hes1/p27Kip1 signaling pathway. FEBS Open Bio 5, 656–660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Aschner Y and Downey GP (2016) Transforming growth factor‐beta: master regulator of the respiratory system in health and disease. Am J Respir Cell Mol Biol 54, 647–655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Chai SD, Liu T, Dong MF, Li ZK, Tang PZ, Wang JT and Ma SJ (2016) Inactivated Pseudomonas aeruginosa inhibits hypoxia‐induced pulmonary hypertension by preventing TGF‐beta1/Smad signaling. Braz J Med Biol Res 49, e5526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Bauer EM, Chanthaphavong RS, Sodhi CP, Hackam DJ, Billiar TR and Bauer PM (2014) Genetic deletion of toll‐like receptor 4 on platelets attenuates experimental pulmonary hypertension. Circ Res 114, 1596–1600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Sun Z (2014) Platelet TLR4: a critical link in pulmonary arterial hypertension. Circ Res 114, 1551–1553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Song Y, Wu Y, Su X, Zhu Y, Liu L, Pan Y, Zhu B, Yang L, Gao L and Li M (2016) Activation of AMPK inhibits PDGF‐induced pulmonary arterial smooth muscle cells proliferation and its potential mechanisms. Pharmacol Res 107, 117–124. [DOI] [PubMed] [Google Scholar]
  • 27. Chuang JI, Huang JY, Tsai SJ, Sun HS, Yang SH, Chuang PC, Huang BM and Ching CH (2015) FGF9‐induced changes in cellular redox status and HO‐1 upregulation are FGFR‐dependent and proceed through both ERK and AKT to induce CREB and Nrf2 activation. Free Radic Biol Med 89, 274–286. [DOI] [PubMed] [Google Scholar]
  • 28. Zheng Y, Ma H, Hu E, Huang Z, Cheng X and Xiong C (2015) Inhibition of FGFR signaling with PD173074 ameliorates monocrotaline‐induced pulmonary arterial hypertension and rescues BMPR‐II expression. J Cardiovasc Pharmacol 66, 504–514. [DOI] [PubMed] [Google Scholar]
  • 29. Garat CV, Crossno JT Jr, Sullivan TM, Reusch JE and Klemm DJ (2013) Inhibition of phosphatidylinositol 3‐kinase/Akt signaling attenuates hypoxia‐induced pulmonary artery remodeling and suppresses CREB depletion in arterial smooth muscle cells. J Cardiovasc Pharmacol 62, 539–548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Lv XB, Liu CY, Wang Z, Sun YP, Xiong Y, Lei QY and Guan KL (2015) PARD3 induces TAZ activation and cell growth by promoting LATS1 and PP1 interaction. EMBO Rep 16, 975–985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Boucherat O, Bonnet S and Paulin R (2016) The HIPPO‐thesis of pulmonary hypertension. Am J Respir Crit Care Med 194, 787–789. [DOI] [PubMed] [Google Scholar]
  • 32. Lan H, Chen W, He G and Yang S (2015) miR‐140‐5p inhibits ovarian cancer growth partially by repression of PDGFRA. Biomed Pharmacother 75, 117–122. [DOI] [PubMed] [Google Scholar]
  • 33. Zhang W, Zou C, Pan L, Xu Y, Qi W, Ma G, Hou Y and Jiang P (2015) MicroRNA‐140‐5p inhibits the progression of colorectal cancer by targeting VEGFA. Cell Physiol Biochem 37, 1123–1133. [DOI] [PubMed] [Google Scholar]

Articles from FEBS Open Bio are provided here courtesy of Wiley

RESOURCES